A J Innes - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

A J Innes

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Bone Marrow Transplantation|July 18, 2017

Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortalityA J Innes, B H Mullish, F Fernando, et al.

British Journal of Haematology|May 3, 2024

Expectations and outcomes of varying treatment strategies for CML presenting during pregnancyH F Robertson, D Milojkovic, N Butt, et al.

Bone Marrow Transplantation|May 21, 2013

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCTA J Innes, R Beattie, R Sergeant, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Bone Marrow Transplantation|July 18, 2017

Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortalityA J Innes, B H Mullish, F Fernando, et al.

British Journal of Haematology|May 3, 2024

Expectations and outcomes of varying treatment strategies for CML presenting during pregnancyH F Robertson, D Milojkovic, N Butt, et al.

Bone Marrow Transplantation|May 21, 2013

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCTA J Innes, R Beattie, R Sergeant, et al.

Pageof 2